Sponsor
Air Force Military Medical University, China
Clinical research sponsor
Clinical trials
26 shownCoil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSNCT07799948 · lead sponsor · 2026-09-01
RECRUITINGTIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal BleedingNCT06635122 · lead sponsor · 2024-07-01
UNKNOWNProspective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingNCT06036563 · lead sponsor · 2023-09-01
UNKNOWNHVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic PatientsNCT04254822 · lead sponsor · 2020-06-01
UNKNOWNApplication of Diffusion Weighted MRI Versus CT in Evaluation of the Effect of Treating Lung CancerNCT02320617 · lead sponsor · 2014-12-01
UNKNOWNStudy of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease PatientsNCT02093195 · lead sponsor · 2013-12-01
UNKNOWNEpidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in ChinaNCT01717092 · lead sponsor · 2012-10-01
UNKNOWNStudy of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension PatientsNCT01712997 · lead sponsor · 2012-09-01
UNKNOWNTIPS With 8- OR 10-mm Covered Stent for Preventing Variceal RebleedingNCT01410591 · lead sponsor · 2012-07-01
COMPLETEDThe Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPSNCT01440829 · lead sponsor · 2011-12-01
COMPLETEDImpact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic PatientsNCT00544518 · lead sponsor · 2007-10-01
UNKNOWNPlasma Exosomal RNA Signature for Prostate Cancer Bone MetastasisNCT07553754 · collaborator · 2026-03-12
RECRUITINGA Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate CancerNCT07474142 · collaborator · 2026-03-03
RECRUITINGPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate CancerNCT07492927 · collaborator · 2021-03-12
RECRUITINGSerial PSMA PET for Therapy Monitoring in Clinically Significant Prostate CancerNCT07553780 · collaborator · 2021-03-07
RECRUITINGDelayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate CancerNCT07531329 · collaborator · 2021-03-05
RECRUITINGLorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNCT06682884 · collaborator · 2024-11-15
NOT_YET_RECRUITINGStudy of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer PatientsNCT04563013 · collaborator · 2020-09-23
COMPLETEDPostmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer PatientsNCT04320979 · collaborator · 2020-05-08
ACTIVE_NOT_RECRUITINGA Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical FeaturesNCT04209166 · collaborator · 2019-08-12
UNKNOWNElectromagnetic Navigation Versus CT Guided TTNA in the Diagnosis of Early Peripheral Lung CancerNCT03802266 · collaborator · 2019-01-01
UNKNOWNOptimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic PatientsNCT03451734 · collaborator · 2018-01-23
COMPLETEDMulti-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological CharacteristicsNCT03219008 · collaborator · 2017-08-01
UNKNOWNComparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesNCT02449603 · collaborator · 2015-11-01
COMPLETEDCancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane AnesthesiaNCT01975064 · collaborator · 2013-11-01
COMPLETEDEfficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in DiabetesNCT01257373 · collaborator · 2010-04-01
UNKNOWNSponsor roles
collaborator15
lead sponsor11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.